| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |